Manan Bhatt

Manan Bhatt

Auto-generated profile, based on publicly available information

Manan Bhatt

Università degli Studi dell'Insubria

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
MBManan Bhatt
Manan Bhatt
AIAngela Di Iacovo
Angela Di Iacovo
TRTiziana Romanazzi
Tiziana Romanazzi
CRCristina Roseti
Cristina Roseti
Elena BossiElena Bossi
Elena Bossi
The role of betaine in the liver and kidney has been well documented, even from the cellular and molecular point of view. Despite literature reporting positive effects of betaine supplementation in Alzheimer's, Parkinson's and schizophrenia, the role and function of betaine in the brain are little studied and reviewed. Beneficial effects of betaine in neurodegeneration, excitatory and inhibitory imbalance and against oxidative stress in the central nervous system (CNS) have been collected and analysed to understand the main role of betaine in the brain. There are many ‘dark’ aspects needed to complete the picture. The understanding of how this osmolyte is transported across neuron and glial cells is also controversial, as the expression levels and functioning of the known protein capable to transport betaine expressed in the brain, betaine‐GABA transporter 1 (BGT‐1), is itself not well clarified. The reported actions of betaine beyond BGT‐1 related to neuronal degeneration and memory impairment are the focus of this work. With this review, we underline the scarcity of detailed molecular and cellular information about betaine action. Consequently, the requirement of detailed focus on and study of the interaction of this molecule with CNS components to sustain the therapeutic use of betaine.

19 June 2024 in Journal of Neurochemistry
Verified
Journal Article
Open access
AAAna Sofia Alberto‐Silva
Ana Sofia Alberto‐Silva
SHSelina Hemmer
Selina Hemmer
HBHailey A. Bock
Hailey A. Bock
LSLeticia Alves da Silva
Leticia Alves da Silva
KSKenneth R. Scott
Kenneth R. Scott
HSHarald H. Sitte
Harald H. Sitte
3,4‐Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is re‐emerging in clinical settings as a candidate for the treatment of specific neuropsychiatric disorders (e.g. post‐traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter‐mediated monoamine release. Despite its therapeutic potential, MDMA can induce dose‐, individual‐, and context‐dependent untoward effects outside safe settings. In this study, we investigated whether three new methylenedioxy bioisosteres of MDMA improve its off‐target profile. In vitro methods included radiotracer assays, transporter electrophysiology, bioluminescence resonance energy transfer and fluorescence‐based assays, pooled human liver microsome/S9 fraction incubations, metabolic stability studies, isozyme mapping, and liquid chromatography coupled to high‐resolution mass spectrometry. In silico methods included molecular docking. Compared with MDMA, all three MDMA bioisosteres (ODMA, TDMA, and SeDMA) showed similar pharmacological activity at human serotonin, dopamine, and norepinephrine transporters (hSERT, hDAT, and hNET, respectively) but decreased agonist activity at 5‐HT2A/2B/2C receptors. Regarding their hepatic metabolism, they differed from MDMA, with N‐demethylation being the only metabolic route shared, and without forming phase II metabolites. In addition, TDMA showed an enhanced intrinsic clearance in comparison to its congeners. Additional screening for their interaction with human organic cation transporters (hOCTs) and plasma membrane monoamine transporter (hPMAT) revealed a weaker interaction of the MDMA analogs with hOCT1, hOCT2, and hPMAT. Our findings suggest that these new MDMA bioisosteres might constitute appealing therapeutic alternatives to MDMA, sparing the primary pharmacological activity at hSERT, hDAT, and hNET, but displaying a reduced activity at 5‐HT2A/2B/2C receptors and alternative hepatic metabolism. Whether these MDMA bioisosteres may pose lower risk alternatives to the clinically re‐emerging MDMA warrants further studies. image

11 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AAAna Sofia Alberto-Silva
Ana Sofia Alberto-Silva
SHSelina Hemmer
Selina Hemmer
HBHailey A. Bock
Hailey A. Bock
LSLeticia Alves da Silva
Leticia Alves da Silva
KSKenneth R. Scott
Kenneth R. Scott
HSHarald H. Sitte
Harald H. Sitte
3,4-Methylenedioxymethamphetamine (MDMA, ‘ ecstasy’ ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic potential, MDMA can induce dose-, individual-, and context-dependent untoward effects outside safe settings. In this study, we investigated whether three new methylenedioxy bioisosteres of MDMA improve its off-target profile. In vitro methods included radiotracer assays, transporter electrophysiology, bioluminescence resonance energy transfer and fluorescence-based assays, pooled human liver microsome/S9 fraction incubation with isozyme mapping, and liquid chromatography coupled to high-resolution mass spectrometry. In silico methods included molecular docking. Compared with MDMA, all three MDMA bioisosteres (ODMA, TDMA, and SeDMA) showed similar pharmacological activity at human serotonin and dopamine transporters (hSERT and hDAT, respectively) but decreased activity at 5-HT 2A/2B/2C receptors. Regarding their hepatic metabolism, they differed from MDMA, with N -demethylation being the only metabolic route shared, and without forming phase II metabolites. Additional screening for their interaction with human organic cation transporters (hOCTs) and plasma membrane transporter (hPMAT) revealed a weaker interaction of the MDMA analogs with hOCT1, hOCT2, and hPMAT. Our findings suggest that these new MDMA analogs might constitute appealing therapeutic alternatives to MDMA, sparing the primary pharmacological activity at hSERT and hDAT, but displaying a reduced activity at 5-HT 2A/2B/2C receptors and reduced hepatic metabolism. Whether these MDMA bioisosteres may pose lower risk alternatives to the clinically re-emerging MDMA warrants further studies.

17 November 2022
Verified
Preprint
Open access
PDF file
MBManan Bhatt
Manan Bhatt
AIAngela Di Iacovo
Angela Di Iacovo
TRTiziana Romanazzi
Tiziana Romanazzi
CRCristina Roseti
Cristina Roseti
EBElena Bossi
Elena Bossi
The role of betaine in the liver and kidney has been well documented, even from the cellular and molecular point of view. Despite literature reporting positive effects of betaine supplementation in Alzheimer’s, Parkinson’s, and Schizophrenia, the role and function of betaine in the brain are little studied and reviewed. Beneficial effects of betaine in neurodegeneration, excitatory and Inhibitory imbalance, and oxidative stress in the central nervous system have been collected and analyzed with the aim of understanding the main role of betaine in the brain. There are many “dark” aspects needed to complete the picture. The understanding of how this osmolyte is transported across neuron and glial cells is also controversial, as the expression levels and functioning of the known protein capable to transport betaine expressed in the brain, betaine-GABA transporter 1 BGT-1, is itself not well clarified. The reported actions of betaine beyond BGT-1 related to neuronal degeneration and memory impairment are the focus of this work. With this review, we underline the scarcity of detailed molecular and cellular information about betaine action. Consequently, the requirement of detailed focus on and study of the interaction of this molecule with CNS components to sustain the therapeutic use of betaine.

1 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MBManan Bhatt
Manan Bhatt
ELErika Lazzarin
Erika Lazzarin
AAAna Sofia Alberto-Silva
Ana Sofia Alberto-Silva
Guido DomingoGuido Domingo
Guido Domingo
RZRocco Zerlotti
Rocco Zerlotti
Elena BossiElena Bossi
Elena Bossi
Betaine is an endogenous osmolyte that exhibits therapeutic potential by mitigating various neurological disorders. However, the underlying cellular and molecular mechanisms responsible for its neuroprotective effects remain puzzling. In this study, we describe a possible mechanism behind the positive impact of betaine in preserving neurons from excitotoxicity. Using electrophysiology, mass spectroscopy, radiolabelled cellular assay, and molecular dynamics simulation we demonstrate that betaine at mM concentration acts as a slow substrate of GAT1 ( slc6a1 ), the predominant GABA transporter in the central nervous system. Intriguingly, when betaine is present at low concentration (0.01-3 mM) with GABA (at concentration <K 0.5 ), it blocks the GABA reuptake. This GAT1 modulation occurs through the temporal inhibition of the transporter, i.e., the prolonged occupancy by betaine impedes the rapid transition of the transporter to the inward conformation. The temporal inhibition results in a crucial regulatory mechanism contributing to the maintenance of GABA homeostasis, preserving neurons from excitotoxicity.

20 June 2024 in Research Square
Verified
Preprint
Open access
PDF file
MBManan Bhatt
Manan Bhatt
ELErika Lazzarin
Erika Lazzarin
AAAna Sofia Alberto-Silva
Ana Sofia Alberto-Silva
GDGuido Domingo
Guido Domingo
RZRocco Zerlotti
Rocco Zerlotti
Elena BossiElena Bossi
Elena Bossi
Betaine is an endogenous osmolyte that exhibits therapeutic potential by mitigating various neurological disorders. However, the underlying cellular and molecular mechanisms responsible for its neuroprotective effects remain puzzling. In this study, we describe a possible mechanism behind the positive impact of betaine in preserving neurons from excitotoxicity. Here we demonstrate that betaine at low concentration modulates the GABA uptake by GAT1 (slc6a1), the predominant GABA transporter in the central nervous system. This modulation occurs through the temporal inhibition of the transporter, wherein prolonged occupancy by betaine impedes the swift transition of the transporter to the inward conformation. Importantly, the modulatory effect of betaine on GAT1 is reversible, as the blocking of GAT1 disappears with increased extracellular GABA. Using electrophysiology, mass spectroscopy, radiolabelled cellular assay, and molecular dynamics simulation we demonstrate that betaine has a dual role in GAT1: at mM concentration acts as a slow substrate, and at µM as a temporal blocker of GABA, when it is below its K0.5. Given this unique modulatory characteristic and lack of any harmful side effects, betaine emerges as a promising neuromodulator of the inhibitory pathways improving GABA homeostasis via GAT1, thereby conferring neuroprotection against excitotoxicity.